BEAM

Beam Therapeutics Inc

BEAM.US beamtx.com + Research + Basket
CIK 0001745999
Employees 540
Phone 857 327 8775
Fiscal year end December
IPO Feb 06, 2020
Address 238 Main Street, Cambridge, MA, United States, 02142
27.23
-1.61 (-5.58%)
USD · NASDAQ
52-week range
20.23
38.26
Trading at 39% of the 52-week range
Market Cap
2.81B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
10.69
Div. Yield
N/A
% Institutions
107.81%
% Insiders
1.20%

1 Year

+14.4%

3 Year

+28.8%

10 Year

+45.2%
Description

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Actions

Add an action for BEAM.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. John M. Evans M.B.A. CEO & Director 1978
Dr. Giuseppe Ciaramella Ph.D. President 1969
Mr. Sravan Kumar Emany Chief Financial Officer 1978
Dr. Christine P. Bellon J.D., Ph.D. Chief Legal Officer & Corporate Secretary 1966
Dr. Amy Simon M.D. Chief Medical Officer 1965
Dr. Feng Zhang Ph.D. Co-Founder NA
Dr. David R. Liu Ph.D. Co-Founder NA
Dr. J. Keith Joung M.D., Ph.D. Co-Founder NA
Ms. Bethany J. Cavanagh M.B.A. Senior VP of Finance, Treasurer & Principal Accounting Officer NA
Dr. Manmohan Singh Ph.D. Chief Technology Officer NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 01, 2026 Amy Simon N/A Sale 6.70K $24.58 $164.69K SEC
Apr 01, 2026 Christine Bellon N/A Sale 5.96K $24.58 $146.40K SEC
Apr 01, 2026 Giuseppe Ciaramella N/A Sale 11.81K $24.58 $290.29K SEC
Apr 01, 2026 John M Evans N/A Sale 30.08K $24.58 $739.32K SEC
Mar 30, 2026 John M Evans N/A Sale 25.00K $22.37 $559.25K SEC
Jan 22, 2026 Christine Bellon N/A Sale 1.37K $34.00 $46.61K SEC
Jan 15, 2026 Christine Bellon N/A Sale 18.63K $34.61 $644.75K SEC
Oct 27, 2025 Fmr Llc N/A Sale 459.00 $26.68 $12.25K SEC
Jul 30, 2025 Fmr Llc N/A Sale 48.37K $20.50 $991.67K SEC
Jul 03, 2025 Amy Simon N/A Sale 876.00 $20.12 $17.63K SEC
Jul 01, 2025 Amy Simon N/A Sale 374.00 $16.94 $6.34K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 12.61M Jun 30, 2026 12.21% $0.02 1.26%
Farallon Capital Management, L.L.C. 10.24M Jun 30, 2026 9.91% $1.62 1.00%
ARK Investment Management LLC 10.23M Jun 30, 2026 9.91% $2.28 -15.65%
BlackRock Inc 9.00M Jun 30, 2026 8.71% $0.00 6.01%
State Street Corp 5.83M Jun 30, 2026 5.64% $0.01 2.24%
Vanguard Portfolio Management, LLC 4.92M Jun 30, 2026 4.76% $0.01 7.67%
Vanguard Capital Management, LLC 4.60M Jun 30, 2026 4.45% $0.00 5.07%
ARCH VENTURE CORP 4.54M Jun 30, 2026 4.40% $14.16 0.00%
Amova Asset Management Americas, Inc 3.46M Jun 30, 2026 3.35% $1.53 -9.69%
Sumitomo Mitsui Trust Group Inc 3.46M Jun 30, 2026 3.35% $0.07 -9.69%
T. Rowe Price Associates, Inc. 3.42M Jun 30, 2026 3.31% $0.01 25.87%
Kynam Capital Management, LP 2.84M Jun 30, 2026 2.75% $5.39 -22.85%
Geode Capital Management, LLC 2.60M Jun 30, 2026 2.51% $0.00 7.38%
Dimensional Fund Advisors, Inc. 2.23M Jun 30, 2026 2.16% $0.01 3.31%
Morgan Stanley - Brokerage Accounts 1.95M Jun 30, 2026 1.89% $0.00 200.95%
Contrarius Group Holdings Ltd 1.61M Jun 30, 2026 1.56% $2.55 202.66%
UBS Asset Mgmt Americas Inc 1.55M Jun 30, 2026 1.50% $0.01 -6.16%
Two Sigma Investments LLC 1.39M Jun 30, 2026 1.34% $0.03 14.65%
Casdin Capital, LLC 1.35M Jun 30, 2026 1.31% $2.32 0.00%
The Goldman Sachs Group Inc 1.31M Jun 30, 2026 1.27% $0.00 30.26%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 ARK Innovation ETF 7.36M 7.12% ▼ 7.25% Sep 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 3.46M 3.35% ▼ 1.87% Sep 30, 2026
3 Fidelity Growth Company Fund 3.46M 3.35% ▲ 0.00% Aug 31, 2026
4 Vanguard MStar Total Stk Mkt Idx Invest 3.29M 3.19% ▲ 0.38% Sep 30, 2026
5 ARK Genomic Revolution ETF 2.66M 2.57% ▲ 0.25% Sep 30, 2026
6 iShares Russell 2000 ETF 2.57M 2.49% ▼ 1.14% Sep 30, 2026
7 Vanguard Small Cap Index 2.33M 2.25% ▼ 1.67% Sep 30, 2026
8 Amova ARK Disruptive Innovation A USD 2.24M 2.17% ▼ 3.73% Aug 31, 2026
9 Vanguard MStar Small Cap Growth Indx Inv 1.29M 1.25% ▼ 4.98% Sep 30, 2026
10 Fidelity Small Cap Index 1.08M 1.05% ▲ 0.88% Jul 31, 2026

Financial Highlights

▼
Market Cap: $2.81B
EBITDA: $-355.78M
Book Value: $10.69
Earnings/Share: $-0.68
Profit Margin: -55.45%
Operating Margin: -25,827.14%
ROA (TTM): -17.01%
ROE (TTM): -8.18%
Revenue (TTM): $156.04M
Revenue/Share (TTM): $1.51
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -94.20%

Valuation Metrics

Enterprise Value: $1.91B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 103.29M
Shares Float: 88.33M
% Insiders: 1.20%
% Institutions: 107.81%
Shares Short: 26.24M
Shares Short (Prior Month): 27.55M
Short Ratio: 13.87
Short % Float: 39.28%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$139.74M
Cost of Goods Sold
adjust
$-22.29M
Gross Profit
subtotal
$117.45M
SG&A
adjust
$-113.82M
R&D
adjust
$-409.62M
Operating Income
subtotal
$-383.69M
Other / Non-Operating Items
adjust
$303.70M
Net Income
subtotal
$-79.99M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BEAM.US!